Zacks Investment Research · Mar 29, 2024
All You Need to Know About Axonics (AXNX) Rating Upgrade to Buy
Axonics (AXNX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NASDAQ · AXNX
Axonics, Inc.
Healthcare · Medical - Devices
$70.98
Up+$0.00 (+0.00%)
Updated Sep 13, 2026, 4:04 PM
SID Score
—
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 3.63B
- P/E ratio
- 527.22
- Dividend yield
- 0.00%
- 52-week range
- — – —
- Volume
- 0
- Avg. volume
- 458.24K
Price performance
AXNX price history
1M range · 0 trading sessions · Daily adjusted prices
AXNX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest AXNX news
The latest Smart Investors Daily articles mentioning AXNX.
Stock researchCompany · Overview
AXNX research
Overview
Company profile and research snapshot.
Company profile
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $71.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Nov 8, 2024 | Needham | Hold | — |
| Aug 5, 2024 | Needham | Hold | — |
| May 6, 2024 | Needham | Hold | — |
| Feb 29, 2024 | RBC Capital | Sector Perform | — |
| Jan 17, 2024 | Needham | Hold | — |
News briefing
No generated briefing is available yet.
Zacks Investment Research · Mar 15, 2024
Axonics (AXNX) Gets CE Mark for Sacral Neuromodulation System
Axonics' (AXNX) fourth-generation rechargeable Sacral Neuromodulation system will reduce the frequency of patient recharges significantly. The new form factor ensures ease of use.
Benzinga · Feb 29, 2024
Beyond The Numbers: 7 Analysts Discuss Axonics Stock
Analysts' ratings for Axonics (NASDAQ:AXNX) over the last quarter vary from bullish to bearish, as provided by 7 analysts. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 6 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 5 0 0 3M Ago 1 0 0 0 0 The 12-month price targets, analyzed by analysts, offer insights with an average target of $71.29, a high estimate of $73.00, and a low estimate of $71.00. Witnessing a positive shift, the current average has risen by 0.69% from the previous average price target of $70.80. Analyzing Analyst Ratings: A Detailed Breakdown The perception of Axonics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Shagun Singh RBC Capital Maintains Sector Perform $71.00 - David Rescott Truist Securities Lowers Hold $71.00 $73.00 David Rescott Truist Securities Lowers Hold $71.00 $73.00 Adam Maeder Piper Sandler Lowers Neutral $71.00 $75.00 Mike Kratky Leerink Partners Announces Market Perform $71.00 - Larry Biegelsen Wells Fargo Raises Equal-Weight $71.00 $68.00 David Rescott Truist Securities Raises Buy $73.00 $65.00 Key Insights: Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or ...Full story available on Benzinga.com
Zacks Investment Research · Feb 14, 2024
American Well Corporation (AMWL) Reports Q4 Loss, Tops Revenue Estimates
American Well Corporation (AMWL) delivered earnings and revenue surprises of 10.53% and 1%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
